Phase II study of sunitinib and irinotecan in patients with recurrent high-grade glioma (HGG).

e12537 Background: The prognosis of patients (pts) with recurrent HGG is poor with a median survival of 3 to 6 months. To date, no second line of treatment is recognized as standard. Enhanced angio...